Letter To My Friend

Here is a message I sent to my friend Susan the other day. Susan is overweight, has diabetes, high cholesterol and her father died of a heart attack at a young age.

She had purchased Bios Life but wasn't compliant in using it before every meal.

I sent this email is to help reinforce her decision to use BiosLife and to remind her to be compliant using it everyday before meals. I also wanted to educate her on the importance of just how great BiosLife is for her health and also for her family and friends. That’s why this recording with Stewart Hughes and Dr Neal Secrist is so important.

Susan saw me taking BiosLife before every meal and asked why and when I explained my reasons to her she bought it, yet wasn't using it.

Taking BiosLife everyday is very important to me for my health. I’m also glad to say Susan now understands how important Bios Life is and also shared with me that her husband was taking it faithfully for a month now and has lowered his cholesterol.

Here is the email I sent her:

Hi Susan,

I thought you might like to listen to a recording Stewart Hughes did last week with Dr. Neal Secrist about BiosLife and Diabetes. It struck a cord in me with what they had to say about diabetes and the effect is has on your pancreas and I really want you to hear this.

Because it’s a high quality recording, when you click on the link, give it a few minutes to download: http://www.usa.makelifebetter.com/it/Stewart_Hughes_Wave_Trimmed.wav the recording is about a half hour long, and well worth listening to.

Susan, if you find this information helpful, will you forward this message to some of your buddies that may have a concern with high cholesterol or diabetes? And Marting might want to send it to his Doctor because he was so impressed with his lower cholesterol because of using the BiosLife.

I Care About Your Health,

T

P.S.

Here’s some information that came out on the news wire a few days ago about Pfizer and all the people that were dying taking their new drug to lower bad cholesterol and raising the good cholesterol. As you know BiosLife does both without any of negative side effects and especially not killing people!!!

Here is the BiosLife chart below that has clinical studies proving it lowers LDL (bad) cholesterol 31% and raising HDL(good) cholesterol 29% So let your let your cardiologists know that he doesn’t have to compromise with drug risks to raise HDL. The right combination already exists with BiosLife.


Here s the Reuters report about Pfizer below:

Pfizer ends cholesterol drug development
Pfizer Inc. said Saturday it has cut off all clinical trials and development for a cholesterol drug that was supposed to be the star of its pipeline because of an unexpected number of deaths and cardiovascular problems in patients who used it.

The world's largest drug maker said it was told Saturday that an independent board monitoring a study for Torcetrapib, a drug that raises levels of HDL, or what's commonly known as good cholesterol, recommended that the work end because of "an imbalance of mortality and cardiovascular events."

Pfizer said it is asking all clinical investigators conducting trials to warn patients to stop taking the drug immediately. The news is devastating to Pfizer, which had been counting on the drug to revitalize stagnant sales that have been hurt by numerous patent expirations on key products.

Just two days ago, Pfizer had said it hoped to file an application with the Food and Drug Administration for approval of Torcetrapib by the second half of next year. But on Saturday, the company said the loss of the drug will not affect its financial guidance for 2006.

New York-based Pfizer had expected to sell Torcetrapib in combination with Lipitor, which lowers bad cholesterol and is the company's #1 and the world's #2 best-selling drug. According to Pfizer spokesman Paul Fitzhenry, 82 patients taking the combination of Torcetrapib died, compared to 51 deaths in the arm of the study where patients were taking Lipitor alone. Each arm of the study had 7,500 patients. Pfizer said that the study didn't raise any questions about Lipitor's safety.

There already had been concerns about Torcetrapib because a study showed it caused an increase in blood pressure. In raising its earnings guidance for the year Thursday the company emphasized that it has 242 research programs and other promising drugs in the pipeline, but analysts remained focused on Torcetrapib and said Pfizer would struggle without it.

Patent expirations will cost the company $14 billion in annual sales between 2005 and 2007, the company said. Lipitor, which had $12.2 billion in sales last year, may lose patent protection by 2010.

Dr. Philip Barter, chairman of the steering committee overseeing the study, said in Pfizer's release that the findings of the data safety monitoring board Torcetrapib were a surprise "in light of prior study results."
"We believed that the study was coming along as expected, and this new information was totally unexpected and disappointing, given the potential benefits of this drug," said Barter, Director of the Heart Research Institute in Australia

Terri Levine
http://www.comprehensivecoachingu.com
http://www.terrilevine.com
http://www.coachinstitute.com/